Gastrointestinal cancer research : GCR最新文献_第9页

The expanding role of somatostatin analogs in the management of neuroendocrine tumors. 生长抑素类似物在神经内分泌肿瘤治疗中的作用日益扩大。

Gastrointestinal cancer research : GCR Pub Date : 2012-09-01

Edward M Wolin

{"title":"The expanding role of somatostatin analogs in the management of neuroendocrine tumors.","authors":"Edward M Wolin","doi":"","DOIUrl":"","url":null,"abstract":"Background: Neuroendocrine tumors (NETs) are neoplasms arising most often in the GI tract, pancreas, or lung. Diagnosis of NETs is often delayed until the disease is advanced, because of the variable and nonspecific nature of the initial symptoms. Surgical resection for cure is therefore not an option for most patients.Methods: Somatostatin analogues represent the cornerstone of therapy for patients with NETs. This article reviews the important role that somatostatin analogues continue to play in the treatment of patients with NETs.Results: Octreotide was the first somatostatin analogue to be developed; more than 30 years of data have accumulated demonstrating its efficacy and safety. Lanreotide is another somatostatin analogue in clinical use, and pasireotide is a promising somatostatin analogue in development. Newer long-acting depot formulations are now available offering once-monthly administration. Although octreotide was initially developed for symptom control, recent results indicate that it also has an antiproliferative effect, significantly increasing time to progression in patients with midgut NETs. Combinations of octreotide with other targeted therapies may further improve patient outcomes. Findings in recent studies of the combination of octreotide and the mTOR inhibitor everolimus are encouraging. The combinations of octreotide with other agents (eg, interferon-α, bevacizumab, cetuximab, AMG-706, and sunitinib) are being investigated.Conclusions: Somatostatin analogues have been used to treat the symptoms of NETs for decades and also have an antineoplastic effect, markedly prolonging progression-free survival. Somatostatin analogues are likely to remain the cornerstone of treatment for most patients with advanced NETs. Promising new combination therapies are undergoing clinical investigation.","PeriodicalId":12695,"journal":{"name":"Gastrointestinal cancer research : GCR","volume":"5 5","pages":"161-8"},"PeriodicalIF":0.0,"publicationDate":"2012-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3481148/pdf/gcr161.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31015137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Huge abdominal tumor: peritoneal solitary fibrous tumor. 巨大腹部肿瘤:腹膜孤立性纤维性肿瘤。

Gastrointestinal cancer research : GCR Pub Date : 2012-09-01

Mahdi Bouassida, Mohamed Mongi Mighri, Dhouha Becha, Lamine Hamzaoui, Selim Sassi, Mohamed Msaddak Azzouz, Hassen Touinsi, Sadok Sassi

引用次数: 0

Durable, complete remission with bevacizumab-based chemotherapy in a patient with metastatic gastroesophageal junction cancer. 以贝伐单抗为基础的化疗使一名转移性胃食管交界处癌患者获得了持久的完全缓解。

Gastrointestinal cancer research : GCR Pub Date : 2012-09-01

Mohammad H Rashid, Mersiha Hadziahmetovic, Uzair B Chaudhary

引用次数: 0

The Past and Future of GI Oncology Research. 胃肠道肿瘤研究的过去与未来。

Gastrointestinal cancer research : GCR Pub Date : 2012-09-01

Daniel G Haller

引用次数: 0

Upcoming articles. 即将到来的文章。

Gastrointestinal cancer research : GCR Pub Date : 2012-09-01

引用次数: 0

Gastrointestinal cancer surgery in patients with a prior ventriculoperitoneal shunt: the department of veterans affairs experience. 既往有脑室-腹膜分流术的胃肠道肿瘤患者的手术:退伍军人事务部的经验。

Gastrointestinal cancer research : GCR Pub Date : 2012-07-01

Shilpi Wadhwa, George K Hanna, Andrew R Barina, Riccardo A Audisio, Katherine S Virgo, Frank E Johnson

{"title":"Gastrointestinal cancer surgery in patients with a prior ventriculoperitoneal shunt: the department of veterans affairs experience.","authors":"Shilpi Wadhwa, George K Hanna, Andrew R Barina, Riccardo A Audisio, Katherine S Virgo, Frank E Johnson","doi":"","DOIUrl":"","url":null,"abstract":"Background: The estimated prevalence of hydrocephalus in all age groups is between 1% and 1.5%. Placement of a ventriculoperitoneal (VP) shunt in such patients offers them relatively normal lives. There are minimal data concerning the risk of postoperative complications in patients with shunts who undergo subsequent major visceral operations. We hypothesized that healthy adults who had VP shunts placed for acquired conditions and later underwent surgery for gastric or colon cancer would frequently have dense, shunt-related adhesions and high rates of adverse outcomes, particularly infection.Methods: We assumed that all veterans were healthy on entry into military service. We searched national Department of Veterans Affairs databases from October 1994 through September 2003 to identify all Department of Veterans Affairs patients with shunts for acquired conditions and a curative-intent operation for stomach or colon cancer. We conducted chart reviews to determine their clinical courses.Results: Five patients had codes for VP shunt, gastric cancer, and gastrectomy; 3 met our inclusion criteria. Fourteen had codes for VP shunt, colon cancer, and colectomy; 4 met our criteria. One of the evaluable gastrectomy patients had dense, shunt-related adhesions. None of the colectomy patients had notable adhesions. There were no postoperative complications in any of the seven patients.Conclusion: We believe this is the first report analyzing the clinical course of adults with VP shunts who later had major abdominal cancer surgery. The presence of a shunt was associated with dense adhesions in 1 (14%) of the 7 patients in this series, but not with an increased risk of postoperative complications.","PeriodicalId":12695,"journal":{"name":"Gastrointestinal cancer research : GCR","volume":"5 4","pages":"125-9"},"PeriodicalIF":0.0,"publicationDate":"2012-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3433261/pdf/gcr125.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30986324","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Communication and palliative care in a 64-year-old man with pancreatic adenocarcinoma. 64岁男性胰腺腺癌患者的沟通与姑息治疗。

Gastrointestinal cancer research : GCR Pub Date : 2012-07-01

Andrew S Epstein, Ghassan K Abou-Alfa, Ali Shamseddine, Ashwaq Al-Olayan, Celina Ang, Mohamed Naghy, Maeve A Lowery, Eileen M O'Reilly

引用次数: 0

New manuscript submission guidelines. 新的稿件提交指南。

Gastrointestinal cancer research : GCR Pub Date : 2012-07-01

Donna Ogilvie

引用次数: 0

Treatment of recurrent pediatric gastrointestinal stromal tumors. 小儿复发性胃肠道间质瘤的治疗。

Gastrointestinal cancer research : GCR Pub Date : 2012-07-01

Manish Dave, Antonio Jimenez, Kateri Evans, William Leslie